NASDAQ:TBPH - Theravance Biopharma Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Theravance Biopharma Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $25.77 -0.13 (-0.50 %) (As of 02/21/2020 04:00 PM ET) Add Compare Today's Range$25.27Now: $25.77▼$25.9250-Day Range$23.63MA: $26.30▼$31.2152-Week Range$15.18Now: $25.77▼$31.54Volume497,786 shsAverage Volume454,369 shsMarket Capitalization$1.46 billionP/E RatioN/ADividend YieldN/ABeta1.92 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Theravance Biopharma, Inc, a diversified biopharmaceutical company, discovers, develops, and commercializes organ-selective medicines. The company offers VIBATIV, a bactericidal, once-daily injectable antibiotic to treat patients with serious, life-threatening infections due to staphylococcus aureus and other gram-positive bacteria, including methicillin-resistant. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TBPH Previous SymbolNASDAQ:TBPHV CUSIPN/A CIK1583107 Webhttp://www.theravance.com/ Phone650-808-6000Debt Debt-to-Equity RatioN/A Current Ratio3.27 Quick Ratio3.27Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$60.37 million Price / Sales24.23 Cash FlowN/A Price / Cash FlowN/A Book Value($0.93) per share Price / Book-27.71Profitability EPS (Most Recent Fiscal Year)($3.99) Net Income$-215,520,000.00 Net Margins-370.54% Return on EquityN/A Return on Assets-43.57%Miscellaneous Employees363 Outstanding Shares56,762,000Market Cap$1.46 billion Next Earnings Date2/24/2020 (Confirmed) OptionableOptionable Receive TBPH News and Ratings via Email Sign-up to receive the latest news and ratings for TBPH and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:TBPH Rates by TradingView Theravance Biopharma (NASDAQ:TBPH) Frequently Asked Questions What is Theravance Biopharma's stock symbol? Theravance Biopharma trades on the NASDAQ under the ticker symbol "TBPH." How were Theravance Biopharma's earnings last quarter? Theravance Biopharma Inc (NASDAQ:TBPH) issued its quarterly earnings data on Tuesday, November, 5th. The biopharmaceutical company reported ($1.05) EPS for the quarter, hitting the Zacks' consensus estimate of ($1.05). The biopharmaceutical company had revenue of $12.43 million for the quarter, compared to the consensus estimate of $13.33 million. View Theravance Biopharma's Earnings History. When is Theravance Biopharma's next earnings date? Theravance Biopharma is scheduled to release their next quarterly earnings announcement on Monday, February 24th 2020. View Earnings Estimates for Theravance Biopharma. How can I listen to Theravance Biopharma's earnings call? Theravance Biopharma will be holding an earnings conference call on Monday, February 24th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available. What price target have analysts set for TBPH? 4 equities research analysts have issued 12-month target prices for Theravance Biopharma's shares. Their forecasts range from $18.00 to $55.00. On average, they anticipate Theravance Biopharma's share price to reach $35.75 in the next twelve months. This suggests a possible upside of 38.7% from the stock's current price. View Analyst Price Targets for Theravance Biopharma. What is the consensus analysts' recommendation for Theravance Biopharma? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Theravance Biopharma in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Theravance Biopharma. What are Wall Street analysts saying about Theravance Biopharma stock? Here are some recent quotes from research analysts about Theravance Biopharma stock: 1. Cantor Fitzgerald analysts commented, ". We believe it is a good time to take another look at TBPH given its inexpensive valuation, and ahead of important catalysts this year. We also note that TBPH’s cash and equivalents totaled $517.1MM as of 12/31/18. It appears well-positioned to receive over $1B in milestones and payments, but its market cap is only ~$1.3B. Therefore, we think the peak sales potential of TBPH’s organ-selective Trelegy, are all underappreciated. Our positive investment thesis supports our OW rating and 12-month PT of $55." (4/12/2019) 2. According to Zacks Investment Research, "Theravance reported narrower-than-expected loss in Q4. Also, revenues beat estimates. The company received a huge boost when the FDA approved Yupelri, the first once daily nebulized LAMA option for COPD, in November. Formal launch activities of Yupelri are currently underway. Meanwhile, the agreement to divest its only marketed drug, Vibativ, will enable Theravance to focus solely on the launch efforts of Yupelri. Moreover, its pipeline programs target highly competitive therapeutic areas. The company's collaboration agreements are a consistent source of funds. However, any agreement termination might be a huge setback for the company as was the case in the past. Shares of the company have underperformed the industry so far this year." (3/13/2019) Has Theravance Biopharma been receiving favorable news coverage? News articles about TBPH stock have trended somewhat positive on Friday, according to InfoTrie. The research firm identifies positive and negative news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Theravance Biopharma earned a coverage optimism score of 1.0 on InfoTrie's scale. They also gave media coverage about the biopharmaceutical company a news buzz of 3.0 out of 10, meaning that recent news coverage is unlikely to have an effect on the stock's share price in the near future. View News Stories for Theravance Biopharma. Are investors shorting Theravance Biopharma? Theravance Biopharma saw a drop in short interest in January. As of January 15th, there was short interest totalling 2,640,000 shares, a drop of 5.4% from the December 31st total of 2,790,000 shares. Based on an average daily volume of 307,900 shares, the days-to-cover ratio is presently 8.6 days. Currently, 6.9% of the shares of the stock are sold short. View Theravance Biopharma's Current Options Chain. Who are some of Theravance Biopharma's key competitors? Some companies that are related to Theravance Biopharma include United Therapeutics (UTHR), Global Blood Therapeutics (GBT), BridgeBio Pharma (BBIO), Evotec (EVTCY), Arrowhead Pharmaceuticals (ARWR), Nektar Therapeutics (NKTR), FibroGen (FGEN), GW Pharmaceuticals PLC- (GWPH), Mirati Therapeutics (MRTX), HUTCHISON CHINA/S (HCM), PTC Therapeutics (PTCT), Zai Lab (ZLAB), SAGE Therapeutics (SAGE), Ultragenyx Pharmaceutical (RARE) and Blueprint Medicines (BPMC). What other stocks do shareholders of Theravance Biopharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Theravance Biopharma investors own include Bausch Health Companies (BHC), Exelixis (EXEL), Gilead Sciences (GILD), Teva Pharmaceutical Industries (TEVA), Immunomedics (IMMU), SCYNEXIS (SCYX), Johnson & Johnson (JNJ), Corbus Pharmaceuticals (CRBP), Progenics Pharmaceuticals (PGNX) and Verastem (VSTM). Who are Theravance Biopharma's key executives? Theravance Biopharma's management team includes the folowing people: Mr. Rick E. Winningham, Chairman & CEO (Age 59)Mr. Bradford J. Shafer, Exec. VP, Gen. Counsel & Sec. (Age 59)Dr. Shehnaaz Suliman M.D., M.Phil., M.B.A., Sr. VP of Corp. Devel. & Strategy (Age 46)Dr. Brett K. Haumann, Sr. VP of Clinical Devel. & Chief Medical Officer (Age 49)Mr. Vijay Sabesan, Sr. VP of Technical Operations Who are Theravance Biopharma's major shareholders? Theravance Biopharma's stock is owned by many different of retail and institutional investors. Top institutional investors include Link Fund Solutions Ltd (9.25%), State Street Corp (1.69%), Chescapmanager LLC (1.67%), Geode Capital Management LLC (1.08%), Jacobs Levy Equity Management Inc. (0.80%) and Candriam Luxembourg S.C.A. (0.49%). Company insiders that own Theravance Biopharma stock include Bradford J Shafer, Burton G Malkiel, Donal O'connor, Philip D Worboys, Renee D Gala, Sharathchandra S Hegde and Vijay Sabesan. View Institutional Ownership Trends for Theravance Biopharma. Which institutional investors are selling Theravance Biopharma stock? TBPH stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG, Citigroup Inc., Virtus ETF Advisers LLC, Bank of America Corp DE, Chicago Equity Partners LLC, New York State Common Retirement Fund, Nisa Investment Advisors LLC and ProShare Advisors LLC. Company insiders that have sold Theravance Biopharma company stock in the last year include Donal O'connor, Sharathchandra S Hegde and Vijay Sabesan. View Insider Buying and Selling for Theravance Biopharma. Which institutional investors are buying Theravance Biopharma stock? TBPH stock was bought by a variety of institutional investors in the last quarter, including Link Fund Solutions Ltd, Chescapmanager LLC, Newtyn Management LLC, Laurion Capital Management LP, Jacobs Levy Equity Management Inc., Credit Suisse AG, First Trust Advisors LP and Cubist Systematic Strategies LLC. View Insider Buying and Selling for Theravance Biopharma. How do I buy shares of Theravance Biopharma? Shares of TBPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Theravance Biopharma's stock price today? One share of TBPH stock can currently be purchased for approximately $25.77. How big of a company is Theravance Biopharma? Theravance Biopharma has a market capitalization of $1.46 billion and generates $60.37 million in revenue each year. The biopharmaceutical company earns $-215,520,000.00 in net income (profit) each year or ($3.99) on an earnings per share basis. Theravance Biopharma employs 363 workers across the globe.View Additional Information About Theravance Biopharma. What is Theravance Biopharma's official website? The official website for Theravance Biopharma is http://www.theravance.com/. How can I contact Theravance Biopharma? Theravance Biopharma's mailing address is UGLAND HOUSE SOUTH CHURCH STREET, GEORGE TOWN E9, KY1-1104. The biopharmaceutical company can be reached via phone at 650-808-6000 or via email at [email protected] MarketBeat Community Rating for Theravance Biopharma (NASDAQ TBPH)Community Ranking: 2.4 out of 5 ( )Outperform Votes: 274 (Vote Outperform)Underperform Votes: 306 (Vote Underperform)Total Votes: 580MarketBeat's community ratings are surveys of what our community members think about Theravance Biopharma and other stocks. Vote "Outperform" if you believe TBPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TBPH will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/21/2020 by MarketBeat.com StaffFeatured Article: How do investors use RSI to grade stocks?
